

March 16, 2006

Edward Hammond
Director Sunshine Project
P.O. Box 41987
Austin, TX 78704

Dear Mr. Hammond

Enclosed are all minutes of the LigoCyte Pharmaceuticals, IBC since 03MAY03.

Sincerely,



Richard Sublett, Ph.D.
Director, Regulatory Affairs and Quality Assurance
Director, Institutional Biosafety Committee
LigoCyte Pharmaceuticals, Inc.
www.ligocyte.com

Encl. IBC Minutes 16MAR05
IBC Minutes 06APR05
IBC Minutes 27APR05
IBC Minutes 20MAY05

Institutional Biosafety Committee

Minutes: 20MAY05

Review and approval of experimentation involving infectious agents titled: "Norvirus VLP Expression in Adenovirus Vectors". This protocol was sent to the IBC committee on 28APR05. Joel Haynes is the Principal Investigator.

Five members approved the protocol.
Members approving the protocol:

Richard Sublett
Robert Bargatze
Gary Zimmerman
Jo-An Lindstrom
Erin E. Dobrinen

Joel Haynes is the PI and did not review this protocol.

Approval forms are on file with the protocol.


RDS
25MA 20MAY05
Richard Sublett, Ph.D.
IBC Chairperson





2155 Analysis Drive • Bozeman, MT 59718 • Ph: 406-585-2733 • Fx: 406-585-2766

Institutional Biosafety Committee

Minutes: 16MAR05

Registration of Experimentation Involving Microbial and Recombinant DNA Hazardous Agents titled: "Norovirus VLP Expression in Baculovirus Vectors, In Vitro use in Research" was sent to the IBC committee on 03MAR05. Joel Haynes is the Principal Investigator.

Five members approved the protocol. Joel Haynes, who is a member of the IBC was not part of the review process. The final approval form was received by the IBC Chairperson on 16MAR05.

Members approving the protocol:

Richard Sublett
Robert Bargatze
Gary Zimmerman
Jo-An Lindstrom
Erin E. Dobrinen
Joel Haynes-PI and did not review

Approval forms are on file with the protocol.

 16 MAR 05

Richard Sublett, Ph.D.
IBC Chairperson



Institutional Biosafety Committee Minutes

Date: 06APR05 11:00 AM LigoCyte Executive Conference Room


Attendees: Jo-An Lindstrom
Gary Zimmerman
Robert Bargatze
Erin E. Dobrinen
Joel Haynes
Richard Sublett
Susan Wimer-Mackin

Agenda:

- 1) Define role of LigoCyte IBC
- 2) Review Infectious Agent Usage Form
- 3) Infectious Agent Usage Form: Development of Vaccines for Anthrax

Meeting Minutes:

- 1) Introductions and review of individual backgrounds of IBC members
- 2) Discussed role of IBC
 - a) Review of rDNA Protocols as required by NIH
 - b) Review Infectious Agent Usage form as required by the CDC for CDC defined Select Agents
 - c) Review of rDNA and Infectious Agent Usage Forms is focused on safety and public health.
 - d) IBC will not assume role of IACUC or review scientific protocols. However purpose of protocols should be defined for the IBC members in the submitted protocols
- 3) Content of Infectious Agent Usage was discussed
 - a) Verbiage would be added stating that EA101 forms must completed and CDC notified of any select agent transfer.
 - b) Verbiage would be added referencing a select agent transport SOP and such an SOP would be drafted.
- 4) Infectious Agent Usage Form: Development of Vaccines for Anthrax was discussed. No recommendations other than those listed above were made.
- 5) Susan Wimer-Mackin agreed to make changes and the new version will be distributed to IBC by email.

 07 APR 05
Richard Sublett, Ph.D.
IBC Chairperson



Institutional Biosafety Committee

Minutes: 27APR05

Review and approval of experimentation involving infectious agents titled: "Infectious Agent Usage Form: Development of Vaccines for Anthrax" was sent to the IBC committee on 07APR05. Susan Wimer-Mackin is the Principal Investigator. This protocol was modified following an IBC meeting on 06APR05.

Six members approved the protocol.
Members approving the protocol:

Richard Sublett
Robert Bargatze
Gary Zimmerman
Jo-An Lindstrom
Erin E. Dobrinen
Joel Haynes

Approval forms are on file with the protocol.


Richard Sublett, Ph.D.
IBC Chairperson

